Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Giovanni, Ponti ^a   Giovanni, Pellacani ^a   Aldo, Tomasi ^a   Pietro, Loschi ^a   Gabriele, Luppi ^a   Fabio, Gelsomino ^a   Caterina, Longo ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; GNAQ PROTEIN; MUTANT PROTEIN; NRAS INHIBITOR; PROTEIN INHIBITOR; RAS PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GENETIC SCREENING; GNAQ GENE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; KERATOACANTHOMA; MALE; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATOR GENE; NAUSEA; ONCOGENE C KIT; ONCOGENE N RAS; PRIORITY JOURNAL; QT PROLONGATION; SOMATIC MUTATION; TREATMENT RESPONSE; VOMITING;

EID: 84893726065     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/671283     Document Type: Article

References (14)

1. Ascierto P. A., Kirkwood J. M., Grob J.-J., Simeone E., Grimaldi A. M., Maio M., Palmieri G., Testori A., Marincola F. M., Mozzillo N., The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine 2012 10, article 85 2-s2.0-84860382327 10.1186/1479-5876-10-85
2. Morita S. Y., Markovic S. N., Molecular targets in melanoma: time for 'ethnic personalization'. Expert Review of Anticancer Therapy 2012 12 5 601 608
3. Davies H., Bignell G. R., Cox C., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 10.1038/nature00766 (Pubitemid 34716871)
4. Maldonado J. L., Fridlyand J., Patel H., Determinants of BRAF mutations in primary melanomas. Journal of the National Cancer Institute 2003 95 24 1878 1890 10.1093/jnci/djg123
5. Curtin J. A., Fridlyand J., Kageshita T., Patel H. N., Busam K. J., Kutzner H., Cho K.-H., Aiba S., Bröcker E.-B., LeBoit P. E., Pinkel D., Bastian B. C., Distinct sets of genetic alterations in melanoma. The New England Journal of Medicine 2005 353 20 2135 2147 2-s2.0-27844567142 10.1056/NEJMoa050092 (Pubitemid 41653105)
6. Ponti G., Pellacani G., Tomasi A., Gelsomino F., Spallanzani A., Depenni R., Al Jalbout S., Simi L., Garagnani L., Borsari S., Conti A., Ruini C., Fontana A., Luppi G., The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. Journal of Clinical Pathology 2013 66 5 441 445
7. Ponti G., Tomasi A., Pellacani G., Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E, V600M) metastatic malignant melanoma. Journal of Hematology & Oncology 2012 5, article 60
8. Curtin J. A., Busam K., Pinkel D., Bastian B. C., Somatic activation of KIT in distinct subtypes of melanoma. Journal of Clinical Oncology 2006 24 26 4340 4346 2-s2.0-33749021085 10.1200/JCO.2006.06.2984 (Pubitemid 46630793)
9. Ambrosini G., Pratilas C. A., Qin L. X., Tadi M., Surriga O., Carvajal R. D., Schwartz G. K., Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clinical Cancer Research 2012 18 13 3552 3561
10. Ambrosini G., Musi E., Ho A. L., de Stanchina E., Schwartz G. K., Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Molecular Cancer Therapeutics 2013 12 5 768 776
11. Abu-Abed S., Pennell N., Petrella T., Wright F., Seth A., Hanna W., KIT gene mutations and patterns of protein expression in mucosal and acral melanoma. Journal of Cutaneous Medicine and Surgery 2012 16 2 135 142 2-s2.0-84860324493 10.2310/7750.2011.11064
12. Shi H., Kong X., Ribas A., Lo R. S., Combinatorial treatments that overcome PDGFR β -driven resistance of melanoma cells toV600EB-RAF inhibition. Cancer Research 2011 71 15 5067 5074 2-s2.0-79960946383 10.1158/0008-5472.CAN-11-0140
13. Nazarian R., Shi H., Wang Q., Kong X., Koya R. C., Lee H., Chen Z., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S. F., McArthur G., Sosman J. A., Ribas A., Lo R. S., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 468 7326 973 977 2-s2.0-78650303507 10.1038/nature09626
14. Johannessen C. M., Boehm J. S., Kim S. Y., Thomas S. R., Wardwell L., Johnson L. A., Emery C. M., Stransky N., Cogdill A. P., Barretina J., Caponigro G., Hieronymus H., Murray R. R., Salehi-Ashtiani K., Hill D. E., Vidal M., Zhao J. J., Yang X., Alkan O., Kim S., Harris J. L., Wilson C. J., Myer V. E., Finan P. M., Root D. E., Roberts T. M., Golub T., Flaherty K. T., Dummer R., Weber B. L., Sellers W. R., Schlegel R., Wargo J. A., Hahn W. C., Garraway L. A., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 468 7326 968 972 2-s2.0-78650309875 10.1038/nature09627